Dr. Isis notes, with some nervousness, that she has had an unanticipated, enormous response to participate in her clinical trial and wonders if the current economic climate is contributing to the interest in her project. Zuska adds that she wouldn't be surprised if that were the reason.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.
The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.
The first Reproducibility Project: Cancer Biology papers show mixed results.
In Nature this week: mobile phone-based targeted DNA sequencing, and more.